Meredith Goldwasser's most recent trade in Prime Medicine Inc was a trade of 90,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | Meredith Goldwasser | SVP, Strategy & Corporate Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 90,500 | 90,500 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Meredith Goldwasser | SVP, Strategy & Corporate Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 90,498 | 90,498 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Meredith Goldwasser | SVP, Strategy & Corporate Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 4,690 | 4,690 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Meredith Goldwasser | SVP, Strategy & Corporate Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 90,498 | 90,498 | - | - | Stock Option (right to buy) |